Performant Financial (PFMT) Q4 2024 earnings summary

Executive summary

• Completed strategic transformation into a dedicated healthcare company, achieving double-digit revenue growth in 2024 with healthcare revenue at $118.3 million, up 11% year-over-year.

• Commercial client revenue grew 18%, now representing over 57% of healthcare revenue, while government revenue grew 3% amid election-related headwinds.

• Implemented 42 new commercial programs in 2024, with over 100 commercial implementations since 2022.

• Transition to a healthcare pure-play since 2021 has expanded the commercial client base and set the stage for new contracts, including the first State Medicaid contract in New York.

• Results for 2024 were within original guidance despite macroeconomic headwinds in the payment integrity sector.

Financial highlights

• Q4 2024 total revenue was $34.8 million, with healthcare revenue at $34.3 million, up from $31.1 million year-over-year.

• Full-year 2024 revenue reached $123 million; healthcare revenue was $118.3 million, up from $106.4 million.

• Adjusted EBITDA for 2024 was $4.4 million, up from $3.4 million in 2023; Q4 adjusted EBITDA was $3.1 million.

• Q4 2024 net loss was $0.5 million ($-0.01/share); full-year net loss was $9.9 million ($-0.13/share).

• Operating expenses for 2024 were $132.5 million, up $12.5 million from 2023, mainly due to scaling and technology investments.

Outlook and guidance

• 2025 revenue guidance is $131–$135 million, with adjusted EBITDA of $8–$9 million, nearly double 2024 at the midpoint.

• Guidance incorporates wind-down of RAC Region 5 and excludes potential upside from new government initiatives.

• Expect $4.5–$5.5 million in net implementation costs and $1–$2 million in Project Turing OpEx in 2025.

• Targeting 20%+ adjusted EBITDA margins as revenues scale to $150–$160 million.

• Focus for 2025 is on margin improvement through technology and scaling.